Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Recce Pharmaceuticals achieves "yet another milestone", receiving ethics approval for Phase I/II diabetic foot ulcer study

Stock Markets Dec 09, 2022 11:30
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Recce Pharmaceuticals achieves "yet another milestone", receiving ethics approval for Phase I/II diabetic foot ulcer study
 
SPPI
+0.52%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received approval from the human research ethics committee (HREC) to kick off its Phase I/II clinical trial assessing RECCE® 327 as a spray-on, broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot infections (DFI).

The Phase I/II clinical trial is a single-centre, prospective, interventional study assessing the safety and efficacy of R327 as a broad-spectrum, topical anti-infective treatment for patients with mild skin and soft tissue DFI.

The trial will enrol up to 32 patients and will be conducted at Sydney South West’s limb preservation and wound research unit, renowned for its innovative and ground-breaking focus on wounds of the limbs and limb loss, an under-researched area in Australian healthcare.

Moving forward, with the patient population readily available, Recce expects the first patients to be dosed by the March quarter of 2023.

"Yet another milestone"

Recce chief executive officer James Graham said: “Receiving HREC approval is yet another milestone for Recce and the clinicians seeking to find an effective therapeutic treatment against DFI.

“This achievement speaks to Recce’s track record of HREC approvals already received and the dedication of our clinical and research team, as we look forward to building out our topical programs.”

Study highlights

The clinical investigation team comprises Professor Hugh Dickson OAM as principal investigator (Consultant Physician in Ambulatory Care), associate professor Slade Jensen (Chair of Infectious Diseases and Microbiology and Western Sydney University, School of Medicine), a team of specialist associate investigators and the Ingham Institute of Applied Medical Research.

Recce is exploring R327 as a preventative treatment for DFI, as studies in the United States have shown between 14-24% of patients with diabetes who develop a foot ulcer will require an amputation, and foot ulceration precedes 85% of diabetes-related amputations.

The study is made possible thanks to the NSW Government Department of Health, at a cost of A$500,000.

Dickson said: “The research indicates that RECCE® 327 may be effective in treating patients with diabetic foot infections.

“The team hopes that its early promise is fulfilled in this study in our patients.”

Forward plan

Ethics approval for this clinical trial is confirmation that the company has completed the necessary pre-clinical safety and efficacy testing of R327 required to commence human clinical trials and runs in addition to its other ongoing clinical trials.

Investigators will review the study data for clinical efficacy and toxicity before deciding to expand the trial to assess the compound’s efficacy against the current best standards of care.

About RECCE® 327

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives with RECCE® 327 being an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to gram-positive and gram-negative bacteria including their superbug forms.

It has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development.

The anti-infective is not yet market-approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Read more on Proactive Investors AU

Disclaimer

Recce Pharmaceuticals achieves "yet another milestone", receiving ethics approval for Phase I/II diabetic foot ulcer study
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email